Dyne reports Q3 net loss $60.2M, cash $157.8M; clinical data due Jan 2024

Dyne Therapeutics, Inc.

2023-Q3 EPS reported -$2.86

Cash, cash equivalents and marketable securities of $157.8M; funding expected through 2024.
Net loss of $60.2M ($0.99 per share) vs. $41.4M ($0.80) in Q3 2022; R&D expenses rose to $55.3M from $34.7M.
ACHIEVE trial (DYNE-101 in DM1) fully enrolled through 3.4 mg/kg; dose escalation to 6.8 mg/kg enrolling; over 150 doses, no anemia or discontinuations.
DELIVER trial (DYNE-251 in DMD) fully enrolled through 10 mg/kg; dose escalation to 20 mg/kg enrolling; over 175 doses, no anemia or discontinuations.
Initial safety, splicing, dystrophin and functional data from both trials expected around J.P. Morgan Healthcare Conference in early January 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Dyne Therapeutics, Inc. reported September 30, 2023 results: net income Net loss for the quarter ended September 30, 2023 was $60.2 million, or $0.99 per basic and diluted share., EPS $0.99.

Period: September 30, 2023
Net income: Net loss for the quarter ended September 30, 2023 was $60.2 million, or $0.99 per basic and diluted share.
EPS: $0.99
Result: reported results

Exact text from the filing

Net loss for the quarter ended September 30, 2023 was $60.2 million, or $0.99 per basic and diluted share.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Dyne Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-056122

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.